Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions

Area of Science:

• Oncology
• Veterinary Medicine
• Pharmacology

Background:

• Feline injection-site sarcomas (ISS) are aggressive tumors requiring effective treatment strategies.
• Masitinib is a selective tyrosine kinase inhibitor with potential anti-cancer properties.
• Radiosensitizers can enhance the efficacy of radiation therapy in cancer treatment.

Purpose of the Study:

• To investigate the potential of masitinib as a radiosensitizer in feline ISS cell lines.
• To determine if masitinib enhances the sensitivity of ISS cells to radiation therapy in vitro.

Main Methods:

• Three primary feline ISS cell lines were used.
• Cell sensitivity to masitinib was assessed using cell growth inhibition assays (IC50 values: 5.5-8.6μM).
• Clonogenic assays were performed to evaluate cell survival after combined masitinib and radiation treatment.

Main Results:

• Both radiation alone and combined masitinib and radiation treatment reduced clonogenic survival in a dose-dependent manner.
• No significant difference in cell survival was observed between radiation alone and the combined treatment.
• Masitinib did not demonstrate direct radiosensitizing effects on feline ISS cells under normal in vitro conditions.

Conclusions:

• Masitinib does not appear to enhance the radiosensitivity of feline injection-site sarcoma cells in vitro.
• Further investigations under altered conditions may be warranted to explore potential radiosensitizing properties of masitinib.
• The findings do not exclude the possibility of masitinib's utility in other contexts or combinations for feline sarcoma treatment.